Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-κB antagonists

Journal of Virology

Volumn 71, Issue 9, 1997, Pages 6486-6494

  Mhashilkar, Abner M ^a   Biswas, Debajit K ^a   LaVecchio, Joyce ^a   Pardee, Arthur B ^a   Marasco, Wayne A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSACTIVATOR PROTEIN;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERMINAL REPEAT; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0030861243     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.9.6486-6494.1997     Document Type: Article

References (60)

1. KB responsive elements for initiation and Tat-mediatcd amplification of HIV transcription in blood CD4 lymphocytes. EMBO J. 14:1552-1560.
2. Baltimore, D. 1988. Intracellular immunization. Nature 335:395-396.
3. Berkhout, B., and K.-T. Jeang. 1989. Transactivation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the transacting responsive hairpin: a quantitative analysis. J. Virol. 63:5501-5504.
4. KB and Tat-induced superactivation of human immunodeficiency virus type 1 long terminal repeat. Proc. Natl. Acad. Sci. USA 90:11044-11048.
5. Biswas, D. K., B. J. Dezube, C. M. Ahlers, and A. B. Pardee. 1993. Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-KB action. J. Acquired Immune Defic. Syndr. 6:778-786.
6. Biswas, D. K., C. M. Ahlers, B. J. Dezube, and A. B. Pardee. 1994, Pemoxifylline and other protein kinase C inhibitors down regulate HIV-LTR NF-KB induced gene expression. Mol. Med. 1:31-43,
7. Biswas, D. K., T. R. Salas, F. Wang, C. M. Ahlers, B. J. Dezube, and A. B. Pardee. 1995. A Tat-induced auto-up-regulatory loop for superactivation of the human immunodeficiency virus type 1 promoter. J. Virol. 69:7437-7444.
8. Bunnell, B. R., L. M. Muul, R. E. Donahue, R. M. Blaese, and R. A. Morgan. 1995. High-efficiency retroviral-mcdiated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc. Natl. Acad. Sci. USA 92:7739-7743.
9. Buonaguro, L., G. Barillari, H.-K. Chang, C. Bohan, V. Kao, R. Morgan, R. C. Gallo, and B. Ensoli. 1992. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J. Virol. 66:7159-7167.
10. Buonaguro, L., F. M. Buonaguro, G. Giraldo, and B. Ensoli. 1994. The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure. J. Virol. 68:2677-2682.
11. Chen, J., Q. Yang, A.-G. Yang, W. A. Murusco, and S.-Y. Chen. 1996. Intra-and extra-cellular immunization against HIV-1 infection with lymphocytes transduced with an AAV vector expressing a human anti-gp120 antibody gene. Human Gene Ther. 7:1515-1525.
12. Chen, S. Y., Y. Khouri, J. Bagley, and W. A. Marasco. 1994. Combined intra and extra-cellular immunization against human immunodeficiency virus type 1 infection using as human anti-gp120 antibody. Proc. Natl. Acad. Sci. USA 91:5932-5936.
13. Chen, S. Y., J. Bagley, and W. A. Marasco. 1994. Intraccllular antibodies as a new class of therapeutic molecules for gene therapy. Hum. Gene Ther. 5:595-600.
14. Cullen, B. R., and W. C. Greene, 1989. Regulatory pathways governing HIV-1 replication. Cell 58:423-426.
15. Cullen, B. R. 1992. Mechanism of action of regulatory proteins encoded by complex retroviruses. Microbiol. Rev. 56:375-394.
16. Dezube, B. J. 1994. Pentoxifylline for the treatment of infection with human immunodeficiency virus. Clin. Infect. Dis. 18:285-287.
17. Dezube, B. J., M. M. Lederman, J. G. Spritzler, B. Chapman, J. A. Korvick, C. Flexner, S. Dando, M. R. Mottiacci, C. M. Ahlers, L. Zhang, et al. 1995. High dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. J. Infect. Dis. 171:1628-1632.
18. Dignam, J. D., R. M. Lebovltz, and R. D. Roeder. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1475-1489.
19. Dingwall, C., I. Ernberg, M. J. Gait, S. M. Green, S. Heaphy, J. Kara, A. D. Lowe, M. Singh, M. A. Skinner, and R. Valero. 1989. Human immunodeficiency virus 1 Tat protein binds trans-activation responsive region (TAR) RNA in vitro, Proc. Natl. Acad. Sci. USA 86:6925-6929.
20. Duan, L., O. Bagasra, M. A. Laughlin, J. W. Oakes, and R. J. Pomerantz. 1994. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single chain antibody. Proc. Natl. Acad. Sci. USA 91:5075-5079.
21. Fauci, A. S., A. M. Macher, D. L. Longo, H. C. Lune, A. H. Rook, H. Masur, and E. P. Gelmann. 1994. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic and therapeutic considerations. Ann. Intern. Med. 100:92-99.
22. Fuzely, F., B. J. Dezube, J. Allen-Ryan, A. B. Pardee, and R. M. Ruprecht. 1991. Pentoxifylline (Trental) decreases the replication of human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T-cells. Blood 77:1653-1656.
23. Gallo, R. C., S. Z. Salahuddin, M. Popovic, G. M. Shearer, M. Kaplan, B. F. Haves, T. J. Palker, R. Redfieid, J. Oleske, B. Safai, G. White, and P. Foster. 1984. Frequent detection and isolation of cytopathic retroviruses (HTLVIII) from patients with AIDS and at risk for AIDS. Science 224:500-503.
24. Gatignol, A., A. Buckler-White, B. Berkhout, and K.-T. Jeang. 1991. Characterization of a human TAR RNA-binding protein that activates the HIV-1 TAR. Science 251:1597-1600.
25. Gaynor, R. E., E. Soultanakis, M. Kuwabara, J. Garcia, and D. S. Sigman. 1989. Specific binding of HeLa cell nuclear protein to RNA sequences in the human immunodeficiency virus transactivating region. Proc. Natl. Acad. Sci. USA 86:4858-4862.
26. Gilboa, E., and C. Smith. 1994. Gene therapy for infectious diseases: the AIDS model. Trends Genet. 10:139-144.
27. Greenblatt, J., J. R. Modwell, and S. W. Mason. 1993. Transcriptional antitermination. Nature 364:401-406.
28. Haseltine, W. A. 1991. Molecular biology of human immunodeficiency virus type-1. FASEB J. 5:2349-2360.
29. Helland, D. E., J. L. Helles, A. Caputo, and W. A. Haseltine. 1991. Transcellular transactivation by the human immunodeficiency virus type 1 Tat protein. J. Virol. 65:4547-4549.
30. Hsu, M.-C., A. D. Schutt, M. Holly, et al. 1991. Inhibition of HIV-1 replication in acute and chronic infectious in-vitro by a tat antagonist. Science 254:1799-1802.
31. Kamine, J., and G. Chinnadurai. 1992. Synergistic activation of the human immunodeficiency virus type I promoter by the viral Tat protein and cellular transcription factor SP1. J. Virol. 66:3926-3932.
32. Kashanchi, F., G. Piras, M. F. Rodonovich, J. F. Duvall, A. Fattaey, C.-M. Chiang, R. G. Roder, and J. N. Brady. 1994. Direct interaction of human TFIID with the HIV-1 transactivator Tat. Nature 367:295-299.
33. Laspia, M. F., A. P. Rice, and M. B. Mathews. 1989. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 59:282-292.
34. Levin, R., A. M. Mhashilkar, T. Dorfman, A. Bukovsky, C. Zani, J. Bagley, J. Hinkula, M. Niedrig, J. Albert, B. Wahren, H. G. Göttlinger, and W. A. Marasco. 1997. Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p 17. Mol. Med. 3:96-110.
35. KB subunits act in concert with Tat to stimulate human immunodeficiency virus type 1 transcription. J. Virol. 66:3883-3887.
36. Maciejewski, J. P., F. F. Weich old, N. S. Young, A. Cara, D. Zella, M. S. Reitz, Jr., and R. C. Gallo. 1995. Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nat. Med. 1:667-673.
37. Madore, S. J., and B. R. Cullen. 1993. Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 tat function. J. Virol. 67:3703-3711.
38. Malim, M. H., J. Hauber, R. Fenrick, and B. R. Cullen. 1988. Immunodeficiency virus rev transactivator modulates the expression of viral regulatory genes. Nature 335:181-183.
39. Marasco, W. A., W. A. Haseltine, and S.-Y. Chen. 1993. Design, intracellular expression and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc. Natl. Acad. Sci. USA 90:7889-7893.
40. Marasco, W. A. 1995. Intracellular antibodies "intrabodies" as research reagents and therapeutic molecules for gene therapy. Immunotechnology 1:119.
41. Marasco, W. A. 1997. Intrabodies: turning the humorol immune system outside in for intracellular immunization. Gene Ther. 4:11-15.
42. Marciniak, R. A., M. A. Garcia-Blanco, and P. A. Sharp. 1990. Identification and characterization of a HeLa nuclear protein that specifically binds to transactivation response (TAR) clement of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 87:3624-3638.
43. Marciniak, R. A., and P. A. Sharp. 1991. HIV-1 Tal protein promotes formation of more processive elongation complexes. EMBO J. 10:4189-4196.
44. Mhashilkar, A. M., J. Bagley, S.-Y. Chen, A. M. Szilvay, D. G. Helland, and W. A. Marasco. 1995. Inhibition of HIV-1 Tat mediated LTR transactivation and HIV-1 infection by anti-Tat single-chain antibodies. EMBO J. 14:1542- 1551.
45. Mhashilkar, A. M., S. Agarwal, S. Levin, and W. A. Marasco. 1996. Genetic- based strategies for control of HIV-1 : Tat and Rev as potential targets. Drug News Perspect. 9(4):220-227.
46. Miller, A. D. 1991. Retroviral vectors. Curr. Top. Microbiol. Immunol. 158: 1-23.
47. Morgan, R. A., K. Cornetta, and W. F. Anderson. 1990. Applications of the polymeraso chain reaction in retroviral-mediated gene transfer and the analysis of gene-marked human TIL cells. Human Gene Ther. 1:135-149.
48. Ohana, B., P. A. Moore, S. R. Ruhen, C. D. Southgate, M. R. Green, and C. A. Rosen. 1993. The type 1 human immunodeficiency virus Tat binding protein is a transcriptional activator belonging to an additional family of evolutionary conserved genes. Proc. Natl. Acad. Sci. USA 90:138-142.
49. 48a.Ott, M., S. Emillani. C. Van Lint, G. Herbein, J. Lovett, N. Chirmule, T. McCloskey, S. Pahwa, and E. Verdin. 1997. Immune hyperactivation of HIV-1-infected T cells by Tat and the CD28 pathway. Science 275:1481-1485.
50. Poznansky, M. C., R. Foxull, I. Ramstedt, R. Coker, A. Mhashilkar, W. A. Marasco, and J. Weber. Intracellular antibodies against Tat and gp120 inhibit the replication of HIV-1 in T-cells from HIV-infected individuals. Human Gene Ther., in press.
51. Qatsha, K. A., C. Rudolph, D. Marine, C. Schachtele, and W. S. May. 1993. Go 6976 selective inhibitor of protein kinase C. is a potent antagonist of human immunodeficiency virus 1 induction from latent/low level producing reservoir cells in vitro. Proc. Natl. Acad. Sci. USA 90:4674-4678.
52. Rosen. C. A., J. G. Sodroski, and W. A. Haseltine. 1985. The location of cis-acting regulatory sequences in the T-cell lymphotropic virus type 111 (HTLV-III/LAV) long terminal repeat. Cell 41:813-823.
53. Roy, S., U. Delling, C.-H. Chen, C. A. Rusen, and N. Sonenberg. 1990. A bulge structure in HIV-1 TAR RNA is required for Tat-binding and Tat-A mediated transactivation. Genes Dev. 4:1365-1373.
54. Roy, S., N. T. Parkin, C. Rosen, J. Itovitch, and N. Sonenberg. 1990. Struc-V tural requirements for trans-activation of human immunodeficiency viruas type 1 long terminal repeat-directed gene expression by Tat: importance of J base pairing, loop sequences, and bulges in the Tat-responsive sequences. J. Virol. 64:1402-1406.
55. Sastry, K. J., R. H. R. Reddy, R. Pandita, K. Totpal, and B. B. Aggarwal. 1990. HIV-1 Tat gene induces tumor necrosis factor B (lymphotoxin) in human B-lymphoblasloid cell line. J. Biol. Chem. 265:20091-20093.
56. Shaheen, F., L. Duan, M. Zhu, O. Bagasra, and R. J. Pomernntz. 1996. J Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle. J. Virol. 70:3392-3400.
57. Sheline, C. T., M. H. Milocco, and K. H. Jones. 1991. Two distinct nuclear transcriptional factors recognize loop and bulge residues of the HIV-1 TAR RNA hair pin. Genes Dev. 8:2508-2520.
58. Shibuya, H., K. Irie, J. Ninimlya-Tsuji, M. Goebit, T. Taniguchi, and K. Matsumoto. 1992. New human gene encoding a positive modulator of HIV Tat mediated transactivation. Nature 357:700-702.
59. Sodroski. J., C. Rosen, F. Wong-Staal, S. Z. Salahuddin, M. Popovic, S. Arya, R. C. Gallo, and W. A. Haseltlne. 1985. Trans-acting transcriptional regulation of the human T-cell leukemia type-III long terminal repent. Science 227:171-173.
60. Westendorp, M. O., M. Li-Weher, R. W. Frank, and P. H. Krummer. 1994. Human immunodeficiency virus type I Tat upregulales interleukin-2 seeretion in activated cells. J. Virol. 68:4177-4185.